Table 2 Dose assessment metrics averaged for all patients for 1 × PCR, 4 × PCR, and 8 × PCR
No. beam fields | Metrics | Strategy | Planning dose | 1 × PCR | 4 × PCR | 8 × PCR | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Mean ± (SD) | Range | Mean ± (SD) | Range | Mean ± (SD) | Range | Mean ± (SD) | Range | |||
1 beam field | D95 (Gy(RBE)) | Ungated | 46.5 ± 0.4 | (45.6-47.4) | 43.7 ± 1.7 | (39.0-46.2) | 46.3 ± 0.4 | (45.4-47.2) | 46.5 ± 0.4 | (45.6-47.3) |
Gated | 46.1 ± 0.6 | (44.8-47.4) | 45.4 ± 0.7 | (42.7-46.8) | 45.9 ± 0.5 | (44.7-46.8) | 46.1 ± 0.6 | (44.7-47.2) | ||
Dmax (Gy(RBE)) | Ungated | 48.7 ± 0.3 | (48.5-49.4) | 56.6 ± 4.7 | (50.4-73.0) | 49.7 ± 0.6 | (49.0-50.9) | 49.0 ± 0.3 | (48.5-49.9) | |
Gated | 48.9 ± 0.3 | (48.5-49.4) | 51.7 ± 1.9 | (49.0-55.2) | 49.9 ± 1.0 | (48.5-53.8) | 49.3 ± 0.5 | (49.0-50.9) | ||
Dmin (Gy(RBE)) | Ungated | 43.4 ± 1.8 | (39.4-47.5) | 39.8 ± 3.0 | (33.1-44.2) | 43.0 ± 1.9 | (38.4-46.6) | 43.3 ± 1.8 | (39.4-47.5) | |
Gated | 43.3 ± 1.4 | (39.8-47.0) | 42.0 ± 1.6 | (36.0-45.1) | 42.8 ± 1.3 | (39.4-46.6) | 43.2 ± 1.3 | (39.8-47.0) | ||
HI (%) | Ungated | 1.1 ± 0.2 | (0.5-1.7) | 5.1 ± 2.3 | (2.0-12.4) | 1.4 ± 0.3 | (0.7-2.3) | 1.2 ± 0.2 | (0.6-1.7) | |
Gated | 1.3 ± 0.4 | (0.6-2.1) | 2.5 ± 0.8 | (1.3-4.4) | 1.7 ± 0.3 | (1.0-2.6) | 1.5 ± 0.4 | (0.7-2.1) | ||
Treatment time (s) | Ungated | N/A | N/A | 99.1 ± 50.7 | (28.3-251.1) | 99.1 ± 50.7 | (28.3-251.1) | 99.1 ± 50.7 | (28.3-251.1) | |
Gated | N/A | N/A | 118.5 ± 55.0 | (44.3-253.9) | 118.8 ± 55.0 | (47.1-269.8) | 119.6 ± 55.5 | (44.9-264.3) | ||
4 beam fields | D95 (Gy(RBE)) | Ungated | 46.7 ± 0.4 | (46.0-47.6) | 45.3 ± 0.9 | (43.0-46.3) | 46.6 ± 0.3 | (46.2-47.5) | 46.7 ± 0.4 | (46.0-47.6) |
Gated | 46.3 ± 0.5 | (45.5-47.6) | 46.1 ± 0.4 | (45.6-46.8) | 46.2 ± 0.4 | (45.6-47.2) | 46.3 ± 0.6 | (45.5-47.5) | ||
Dmax (Gy(RBE)) | Ungated | 48.5 ± 0.1 | (48.5-49.0) | 52.6 ± 2.2 | (49.9-56.2) | 48.9 ± 0.3 | (48.5-49.4) | 48.6 ± 0.2 | (48.5-49.0) | |
Gated | 48.6 ± 0.2 | (48.5-49.0) | 49.8 ± 0.8 | (49.0-50.9) | 49.0 ± 0.5 | (48.5-50.4) | 48.8 ± 0.3 | (48.5-49.4) | ||
Dmin (Gy(RBE)) | Ungated | 44.2 ± 1.7 | (40.3-47.5) | 42.7 ± 1.8 | (39.4-45.1) | 44.2 ± 1.7 | (40.3-47.5) | 44.2 ± 1.6 | (40.8-47.5) | |
Gated | 44.4 ± 1.1 | (42.7-47.5) | 44.0 ± 0.7 | (43.2-46.1) | 44.2 ± 0.8 | (43.2-46.6) | 44.3 ± 1.1 | (42.7-47.5) | ||
HI (%) | Ungated | 0.9 ± 0.2 | (0.3-1.2) | 2.9 ± 1.1 | (1.5-5.6)) | 1.0 ± 0.2 | (0.4-1.2) | 0.9 ± 0.2 | (0.3-1.2) | |
Gated | 1.1 ± 0.3 | (0.3-1.6) | 1.5 ± 0.3 | (1.1-2.0)) | 1.2 ± 0.2 | (0.7-1.6) | 1.2 ± 0.3 | (0.4-1.7) | ||
Treatment time (s) | Ungated | N/A | N/A | 396.4 ± 195.4 | (180.7-915.8) | 396.4 ± 195.4 | (180.7-915.8) | 396.4 ± 195.4 | (180.7-915.8) | |
Gated | N/A | N/A | 474.1 ± 218.6 | (235.1-939.1) | 475.1 ± 218.7 | (234.5-960.6) | 478.5 ± 220.2 | (239.2-956.7) | ||